These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23359475)

  • 1. Pharmacologic therapy for nonalcoholic fatty liver disease in adults.
    Malinowski SS; Byrd JS; Bell AM; Wofford MR; Riche DM
    Pharmacotherapy; 2013 Feb; 33(2):223-42. PubMed ID: 23359475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing nonalcoholic fatty liver disease: recommendations for family physicians.
    Grattagliano I; Portincasa P; Palmieri VO; Palasciano G
    Can Fam Physician; 2007 May; 53(5):857-63. PubMed ID: 17872748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.
    Tiniakos DG
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):643-50. PubMed ID: 19478676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and nonalcoholic fatty liver disease: a bright future?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1089-93. PubMed ID: 23889731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epidemiology and natural history of nonalcoholic fatty liver disease].
    Pais R; Ratziu V
    Rev Prat; 2012 Dec; 62(10):1416-8, 1420-1. PubMed ID: 23424924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.
    Nseir W; Mahamid M
    Curr Atheroscler Rep; 2013 Mar; 15(3):305. PubMed ID: 23328905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.
    Milić S; Stimac D
    Dig Dis; 2012; 30(2):158-62. PubMed ID: 22722431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging therapies in nonalcoholic fatty liver disease.
    Kashi MR; Torres DM; Harrison SA
    Semin Liver Dis; 2008 Nov; 28(4):396-406. PubMed ID: 18956296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective.
    Lackner C
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):223-31. PubMed ID: 21476917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Stein LL; Dong MH; Loomba R
    Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pediatric nonalcoholic fatty liver disease/nonalcoholic steatohepatitis].
    Takahashi Y; Fukusato T; Inui A; Fujisawa T
    Nihon Rinsho; 2012 Oct; 70(10):1827-34. PubMed ID: 23198569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD).
    Mishra P; Younossi ZM
    Curr Drug Discov Technol; 2007 Aug; 4(2):133-40. PubMed ID: 17691915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASH and NASH.
    Scaglioni F; Ciccia S; Marino M; Bedogni G; Bellentani S
    Dig Dis; 2011; 29(2):202-10. PubMed ID: 21734385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease.
    Rubinstein E; Lavine JE; Schwimmer JB
    Semin Liver Dis; 2008 Nov; 28(4):380-5. PubMed ID: 18956294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.